Literature DB >> 33510739

Susceptibility of Clinical Enterobacterales Isolates With Common and Rare Carbapenemases to Mecillinam.

Frieder Fuchs1, Aysel Ahmadzada1, Lars Plambeck1, Thorsten Wille1, Axel Hamprecht1,2,3.   

Abstract

Purpose: To investigate the susceptibility of carbapenemase-producing Enterobacterales (CPE) to mecillinam based on the recently updated European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints for uncomplicated Urinary Tract Infection (uUTI).
Methods: The challenge collection consisted of 105 molecularly characterized Enterobacterales [Klebsiella spp. (N = 49), Escherichia coli (N = 30), Enterobacter cloacae (n = 13), Citrobacter freundii (N = 9), Proteus mirabilis (N = 3), and Raoultella ornithinolytica (N = 1)]. Isolates produced OXA-48 (N = 18), OXA-48-like (N = 18), VIM (N = 22), NDM (N = 22), KPC (N = 12), IMI (N = 9), IMP (N = 6), GES (N = 1), OXA-58 (N = 2) or combinations thereof (N = 5). MICs of carbapenems were determined by agar gradient diffusion (AGD). MICs of mecillinam were assessed by agar dilution (reference method) and compared to disk diffusion (DD) and AGD.
Results: Overall 23/105 CPE (21.9%) were susceptible to mecillinam. Susceptibility was observed in E. coli (N = 12), E. cloacae (N = 7), and Klebsiella pneumoniae (N = 4) producing IMI, OXA-48, OXA-48-like, and NDM-1 carbapenemases. MIC50 for mecillinam in all isolates was 128 mg/L while MIC50 for meropenem was 8 mg/L. Lower MICs for mecillinam were found in IMI (MIC50 8 mg/L) and OXA-48-like (MIC50 16 mg/L) producers. The comparison of the different susceptibility methods showed very major errors of 12.2% with AGD and 8.5% with disk diffusion when compared to the reference method.
Conclusion: Mecillinam susceptibility was restricted to isolates producing IMI-, OXA-48-like, and NDM-1 carbapenemases and was documented despite high carbapenem MICs in some isolates. Mecillinam could be a promising oral antimicrobial in uUTI caused by E. coli and E. cloacae isolates carrying IMI- and OXA-48-like carbapenemases; however, susceptibility testing by AGD and disk diffusion remains problematic.
Copyright © 2021 Fuchs, Ahmadzada, Plambeck, Wille and Hamprecht.

Entities:  

Keywords:  CPE; IMI; NDM; OXA-48; UTI; amdinocillin; multidrug-resistant; pivmecillinam

Year:  2021        PMID: 33510739      PMCID: PMC7835630          DOI: 10.3389/fmicb.2020.627267

Source DB:  PubMed          Journal:  Front Microbiol        ISSN: 1664-302X            Impact factor:   5.640


  29 in total

1.  EUCAST Definitive Document E.DEF 3.1, June 2000: Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution.

Authors: 
Journal:  Clin Microbiol Infect       Date:  2000-09       Impact factor: 8.067

2.  Activity of mecillinam against ESBL producers in vitro.

Authors:  K Thomas; M J Weinbren; M Warner; N Woodford; D Livermore
Journal:  J Antimicrob Chemother       Date:  2005-12-14       Impact factor: 5.790

3.  Rapid detection of OXA-48-like, KPC, NDM, and VIM carbapenemases in Enterobacterales by a new multiplex immunochromatographic test.

Authors:  Christopher Greissl; Ahmad Saleh; Axel Hamprecht
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-11-17       Impact factor: 3.267

4.  In vitro activity of mecillinam against Enterobacteriaceae with NDM-1 carbapenemase.

Authors:  Emma C L Marrs; Kathryn M Day; John D Perry
Journal:  J Antimicrob Chemother       Date:  2014-06-10       Impact factor: 5.790

Review 5.  Optimal dosage and duration of pivmecillinam treatment for uncomplicated lower urinary tract infections: a systematic review and meta-analysis.

Authors:  Mariona Pinart; Jennifer Kranz; Katrin Jensen; Tanja Proctor; Kurt Naber; Frank Kunath; Florian Wagenlehner; Stefanie Schmidt
Journal:  Int J Infect Dis       Date:  2017-03-21       Impact factor: 3.623

Review 6.  Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review.

Authors:  Annarita Mazzariol; Alda Bazaj; Giuseppe Cornaglia
Journal:  J Chemother       Date:  2017-12       Impact factor: 1.714

Review 7.  [Epidemiology, diagnostics, therapy, prevention and management of uncomplicated bacterial outpatient acquired urinary tract infections in adult patients : Update 2017 of the interdisciplinary AWMF S3 guideline].

Authors:  J Kranz; S Schmidt; C Lebert; L Schneidewind; W Vahlensieck; U Sester; R Fünfstück; S Helbig; W Hofmann; E Hummers; M Kunze; E Kniehl; K Naber; F Mandraka; B Mündner-Hensen; G Schmiemann; F M E Wagenlehner
Journal:  Urologe A       Date:  2017-06       Impact factor: 0.639

8.  Results from a Prospective In Vitro Study on the Mecillinam (Amdinocillin) Susceptibility of Enterobacterales.

Authors:  Frieder Fuchs; Axel Hamprecht
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 9.  The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide.

Authors:  P Nordmann; L Poirel
Journal:  Clin Microbiol Infect       Date:  2014-09       Impact factor: 8.067

10.  Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.

Authors:  Marya D Zilberberg; Brian H Nathanson; Kate Sulham; Weihong Fan; Andrew F Shorr
Journal:  BMC Infect Dis       Date:  2017-04-17       Impact factor: 3.090

View more
  2 in total

1.  Activity of mecillinam against carbapenem-resistant Enterobacterales.

Authors:  Cécile Emeraud; Alexandre Godmer; Delphine Girlich; Océane Vanparis; Fériel Mahamdi; Elodie Creton; Agnès B Jousset; Thierry Naas; Rémy A Bonnin; Laurent Dortet
Journal:  J Antimicrob Chemother       Date:  2022-09-30       Impact factor: 5.758

2.  In vitro activity of mecillinam, temocillin and nitroxoline against MDR Enterobacterales.

Authors:  Lars Plambeck; Frieder Fuchs; Janko Sattler; Axel Hamprecht
Journal:  JAC Antimicrob Resist       Date:  2022-06-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.